Total Payments
$23,096
2024 Payments
$891.13
Companies
17
Transactions
69
Medicare Patients
12,388
Medicare Billing
$9.1M
Payment Breakdown by Category
Consulting$12,330 (53.4%)
Other$4,831 (20.9%)
Research$3,701 (16.0%)
Food & Beverage$2,059 (8.9%)
Gifts$175.63 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,330 | 3 | 53.4% |
| Unspecified | $3,701 | 19 | 16.0% |
| Acquisitions | $2,772 | 1 | 12.0% |
| Food and Beverage | $2,059 | 38 | 8.9% |
| Current or prospective ownership or investment interest | $1,560 | 6 | 6.8% |
| Grant | $500.15 | 1 | 2.2% |
| Gift | $175.63 | 1 | 0.8% |
Payments by Type
General
$19,395
50 transactions
Research
$3,701
13 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $10,389 | 17 | $0 (2024) |
| Welch Allyn | $5,850 | 1 | $0 (2018) |
| US Retina LLC | $4,331 | 13 | $0 (2022) |
| ABBVIE INC. | $715.93 | 3 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $326.88 | 9 | $0 (2024) |
| Carl Zeiss Meditec, Inc. | $175.63 | 1 | $0 (2020) |
| Alimera Sciences, Inc. | $166.61 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $164.45 | 3 | $0 (2022) |
| Genentech USA, Inc. | $162.12 | 9 | $0 (2023) |
| Alcon Vision LLC | $141.85 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $891.13 | 9 | ABBVIE INC. ($500.15) |
| 2023 | $284.40 | 6 | Alimera Sciences, Inc. ($166.61) |
| 2022 | $3,668 | 8 | US Retina LLC ($3,437) |
| 2021 | $500.78 | 4 | US Retina LLC ($371.42) |
| 2020 | $7,839 | 8 | Regeneron Pharmaceuticals, Inc. ($7,315) |
| 2019 | $3,460 | 18 | Regeneron Pharmaceuticals, Inc. ($2,866) |
| 2018 | $5,975 | 6 | Welch Allyn ($5,850) |
| 2017 | $478.48 | 10 | Dutch Ophthalmic, USA ($141.73) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $44.91 | General |
| Category: Ophthalmology | ||||||
| 11/12/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $149.94 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/14/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/10/2024 | Bausch & Lomb Americas Inc. | STELLARIS (Device) | Food and Beverage | In-kind items and services | $35.93 | General |
| Category: Ophthalmology | ||||||
| 08/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/19/2024 | Genentech, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $78.55 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/09/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/29/2024 | ABBVIE INC. | OZURDEX (Drug) | Grant | Cash or cash equivalent | $500.15 | General |
| Category: EYE CARE | ||||||
| 12/19/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/16/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $116.61 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/16/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/03/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/29/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/02/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $58.29 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/31/2022 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $2,771.54 | General |
| 12/13/2022 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/24/2022 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/01/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $25.73 | General |
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $578.70 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $87.00 | General |
| 02/02/2022 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $63.89 | General |
| Category: OPHTHALMOLOGY | ||||||
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 10/09/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $129.36 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/11/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $322.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity | Regeneron Pharmaceuticals, Inc. | $2,866 | 12 |
| RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVITREAL AFLIBERCEPT COMPARED TO LASER PHOTOCOAGULATION IN PATIENTS WITH RETINOPATHY OF PREMATURITY | Regeneron Pharmaceuticals, Inc. | $834.75 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,022 | 4,399 | $3.7M | $1.2M |
| 2022 | 13 | 3,344 | 8,625 | $6.9M | $2.4M |
| 2021 | 14 | 3,614 | 9,710 | $7.9M | $2.8M |
| 2020 | 13 | 3,408 | 9,816 | $8.0M | $2.8M |
Total Patients
12,388
Total Services
32,550
Medicare Billing
$9.1M
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 208 | 1,460 | $2.9M | $1.0M | 34.8% |
| 67028 | Injection of drug into eye | Office | 2023 | 233 | 661 | $363,550 | $59,597 | 16.4% |
| 92134 | Imaging of retina | Office | 2023 | 553 | 1,093 | $136,585 | $30,140 | 22.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 313 | 331 | $87,715 | $28,524 | 32.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 177 | 204 | $55,080 | $21,207 | 38.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 187 | 235 | $46,925 | $13,226 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 68 | $18,360 | $6,140 | 33.4% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 45 | 45 | $14,175 | $4,461 | 31.5% |
| 92250 | Photography of the retina | Office | 2023 | 140 | 169 | $16,055 | $3,970 | 24.7% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 47 | 52 | $9,880 | $3,229 | 32.7% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 20 | 44 | $6,600 | $2,266 | 34.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $5,950 | $1,913 | 32.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 15 | 20 | $3,000 | $729.80 | 24.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 300 | 2,820 | $5.6M | $2.0M | 35.7% |
| 67028 | Injection of drug into eye | Office | 2022 | 338 | 1,316 | $723,800 | $122,232 | 16.9% |
| 92134 | Imaging of retina | Office | 2022 | 861 | 2,074 | $176,290 | $59,608 | 33.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 507 | 563 | $112,600 | $50,929 | 45.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 360 | 675 | $84,375 | $43,308 | 51.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 294 | 364 | $72,800 | $34,841 | 47.9% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 118 | 118 | $23,600 | $11,715 | 49.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 112 | 130 | $19,500 | $11,411 | 58.5% |
| 92250 | Photography of the retina | Office | 2022 | 247 | 298 | $28,310 | $7,963 | 28.1% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 96 | 103 | $15,450 | $5,903 | 38.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $10,125 | $4,703 | 46.5% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 41 | 90 | $9,550 | $4,560 | 47.7% |
About Dr. Clio Harper, MD
Dr. Clio Harper, MD is a Ophthalmology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013989706.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Clio Harper, MD has received a total of $23,096 in payments from pharmaceutical and medical device companies, with $891.13 received in 2024. These payments were reported across 69 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($12,330).
As a Medicare-enrolled provider, Harper has provided services to 12,388 Medicare beneficiaries, totaling 32,550 services with total Medicare billing of $9.1M. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Ophthalmology
- Location Austin, TX
- Active Since 02/06/2006
- Last Updated 12/18/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1013989706
Products in Payments
- EYLEA (Biological) $10,466
- RetinaVue Network (Device) $5,850
- OZURDEX (Drug) $628.37
- EYLEA HD (Biological) $249.88
- Humira (Biological) $215.78
- CLARUS (Device) $175.63
- ILUVIEN (Drug) $166.61
- BEOVU (Drug) $146.00
- Constellation (Device) $141.85
- EVA Ophthalmic Surgical System (Device) $141.73
- Prokera (Device) $122.35
- Lucentis (Biological) $112.69
- Spectralis (Device) $109.86
- Vabysmo (Drug) $102.25
- Stellaris (Device) $44.91
- STELLARIS (Device) $35.93
- (820) Cholbam (Drug) $11.06
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Austin
Vikram Durairaj, Md, MD
Ophthalmology — Payments: $516,103
Ophthalmology $516,103
Dr. Sheila Barbarino, M.d, M.D
Ophthalmology — Payments: $236,894
Ophthalmology $236,894
Dr. Thomas Walters, Md, MD
Ophthalmology — Payments: $217,539
Ophthalmology $217,539
Chirag Jhaveri, M.d, M.D
Ophthalmology — Payments: $211,408
Ophthalmology $211,408
Dr. Steven Dell, M.d, M.D
Ophthalmology — Payments: $177,840
Ophthalmology $177,840
Dr. Aaron Roller, M.d, M.D
Ophthalmology — Payments: $154,063
Ophthalmology $154,063